BI 425809

Drug Profile

BI 425809

Alternative Names: BI-425809

Latest Information Update: 05 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antidementias
  • Mechanism of Action Glycine transporter 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cognition disorders

Most Recent Events

  • 20 Jun 2017 Boehringer Ingelheim completes a phase I trial in Healthy volunteers in Germany (NCT03082183)
  • 28 Mar 2017 Boehringer Ingelheim initiates enrolment in a phase I trial in Healthy volunteers in Germany (NCT03082183)
  • 10 Mar 2017 Boehringer Ingelheim plans a phase I trial in Healthy volunteers in Germany (NCT03082183)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top